Navigation Links
Patients can report statins' adverse effects on new web site

A new web site at the University of California, San Diego (UCSD) School of Medicine ? ?will enable people from around the world to self-report adverse effects of statin drug use, or use of other cholesterol drugs.

"This line of research is important because many physicians and other experts in heart disease and cholesterol are familiar with the benefits of statins and other cholesterol drugs, but are unfamiliar with the adverse experiences with these drugs that many people have reported ?such as effects on muscle pain or weakness, memory and thinking, or mood," said Beatrice A. Golomb, M.D., Ph.D., Associate Professor of Medicine, and head of the UCSD Statin Study.

A statin is any of a class of lipid-lowering drugs that reduce serum cholesterol levels by inhibiting a key enzyme involved in the biosynthesis of cholesterol. Statin cholesterol-lowering drugs are among the most prescribed drugs in the United States. According to Consumer Reports, two such drugs ?atorvastatin (Lipitor) and simvastatin (Zocor) ?were #1 and #2 best-selling drugs in the country in 2004, with 75 million prescriptions for Lipitor alone. Although pharmaceutical companies report that side effects of statin drugs are rare, there are some patients who experience serious consequences of taking these drugs.

"We received many calls from patients in the community experiencing side effects, and wanting answers about what to expect. We developed this web site as a tool to gather information on side effects, and to help answer these questions," said Golomb.

The site will provide access to a broad group of people, facilitating the opportunity for patients to confidentially share information about their experience, said Golomb, who adds that a comprehensive understanding of the impact of cholesterol-lowering medications, including statins, has not been undertaken. The site also provides information on st atin use, including what users can expect and ways in which they can minimize health risks.

Golomb has been actively researching the effects of statin medications for the past seven years. She and the research team at UCSD School of Medicine are currently completing an NIH-funded study of 1,000 subjects to evaluate the effects of statin drugs on cognition, behavior and serotonin biochemistry. According to Golomb, among people who have contacted the UCSD Statin Study to report adverse effects, nearly 60% of patients reported muscle weakness or fatigue, and about half reported cognitive problems.

"We believe it is important to understand the full spectrum of effects, both beneficial and adverse," said Golomb. "Our work is geared toward expanding knowledge of the impact of statins in order to better inform the public and the medical community. By filling out the web site survey, statin patients can help us to help others with the same concerns."

Source:University of California - San Diego

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. Implanted Devices Detect High-Risk Heart Failure Patients
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
7. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
8. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
9. IMF Launches World’s First DNA Database for Myeloma Patients
10. Patients now surviving once-fatal immune disease
11. Patients and their doctors have different perceptions about HIV and its treatment

Post Your Comments:

(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology: